Skip to main content
SpringerLink
Log in

Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The dipeptidyl peptidase-4 inhibitor alogliptin (Nesina®, Vipidia®) is approved in numerous countries worldwide for the treatment of type 2 diabetes mellitus. Fixed-dose combinations of alogliptin/metformin (Kazano®, Vipdomet®) and alogliptin/pioglitazone (Oseni®, Incresync®) are also available. This article reviews the clinical efficacy and tolerability of oral alogliptin in the treatment of type 2 diabetes. Results of randomized controlled trials demonstrated that oral alogliptin improved glycaemic control when administered as monotherapy, as dual therapy in combination with metformin, pioglitazone, a sulfonylurea, voglibose or insulin, or as triple therapy in combination with metformin plus pioglitazone. Alogliptin was generally well tolerated in patients with type 2 diabetes and was weight neutral, with a low risk of hypoglycaemia. Results of the large, well designed EXAMINE trial revealed that alogliptin was not associated with an increased risk of major cardiovascular events in patients with type 2 diabetes and recent acute coronary syndrome. In conclusion, alogliptin is a useful option for the treatment of patients with type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.

    Article  CAS  PubMed  Google Scholar 

  2. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14(15):2047–58.

    Article  CAS  PubMed  Google Scholar 

  3. Capuano A, Sportiello L, Maiorino MI, et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy: focus on alogliptin. Drug Des Dev Ther. 2013;7:989–1001.

    Google Scholar 

  4. Takeda Pharmaceuticals America Inc. Nesina (alogliptin) tablets: US prescribing information. 2013. http://www.takeda.us/products/default.aspx. Accessed 3 Mar 2015.

  5. European Medicines Agency. Vipidia (alogliptin): EU summary of product characteristics. 2014. http://www.ema.europa.eu/. Accessed 3 Mar 2015.

  6. Takeda Pharmaceuticals America Inc. Kazano (alogliptin and metformin HCl) tablets for oral administration: US prescribing information. 2013. http://www.takeda.us/products/default.aspx. Accessed 3 Mar 2015.

  7. European Medicines Agency. Vipdomet (alogliptin/metformin): EU summary of product characteristics. 2015. http://www.ema.europa.eu/. Accessed 3 Mar 2015.

  8. Takeda Pharmaceuticals America Inc. Oseni (alogliptin and pioglitazone) tablets: US prescribing information. 2013. http://www.takeda.us/products/default.aspx. Accessed 3 Mar 2015.

  9. European Medicines Agency. Incresync (alogliptin/pioglitazone): EU summary of product characteristics. 2015. http://www.ema.europa.eu/. Accessed 3 Mar 2015.

  10. Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007;50(10):2297–300.

    Article  CAS  PubMed  Google Scholar 

  11. Christopher RJ, Davenport JM, Gwaltney S, et al. Pharmacokinetic and pharmacodynamic profiles of SYR-322, a novel inhibitor of dipeptidyl peptidase-IV, in rats, dogs, and monkeys [abstract no. 452-P]. In: 66th Annual Scientific Sessions of the American Diabetes Association. 2006.

  12. Seino Y, Fujita T, Hiroi S, et al. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin. 2011;27(9):1781–92.

    Article  CAS  PubMed  Google Scholar 

  13. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008;30(3):499–512.

    Article  CAS  PubMed  Google Scholar 

  14. Hirayama M, Matsuno K, Fujita H, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin in Japanese healthy male subjects [abstract no. 521-P]. In: 68th Scientific Sessions of the American Diabetes Association. 2008.

  15. Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008;30(3):513–27.

    Article  CAS  PubMed  Google Scholar 

  16. Van Raalte DH, van Genugten RE, Eliasson B, et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of beta-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol. 2014;170(4):565–74.

    Article  PubMed  Google Scholar 

  17. Seino Y, Hiroi S, Hirayama M, et al. Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. J Diabetes Investig. 2012;3(6):517–25.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Seino Y, Miyata Y, Hiroi S, et al. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab. 2012;14(10):927–36.

    Article  CAS  PubMed  Google Scholar 

  19. Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab. 2014;16(7):613–21.

    Article  CAS  PubMed  Google Scholar 

  20. Nauck MA, Ellis GC, Fleck PR, et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63(1):46–55.

    Article  CAS  PubMed  Google Scholar 

  21. Kaku K, Itayasu T, Hiroi S, et al. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab. 2011;13(11):1028–35.

    Article  CAS  PubMed  Google Scholar 

  22. Seino Y, Fujita T, Hiroi S, et al. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin. 2011;27(Suppl 3):21–9.

    Article  CAS  PubMed  Google Scholar 

  23. Kutoh E, Ukai Y. Alogliptin as an initial therapy in patients with newly diagnosed, drug naive type 2 diabetes: a randomized, control trial. Endocrine. 2012;41(3):435–41.

    Article  CAS  PubMed  Google Scholar 

  24. Eliasson B, Möller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia. 2012;55(4):915–25.

    Article  CAS  PubMed  Google Scholar 

  25. Jurczyk A, Dilorio P, Brostowin D, et al. Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rγ null mice treated with alogliptin. Diabetes Metab Syndr Obes. 2013;6:493–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  26. Zhang X, Wang Z, Huang Y, et al. Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice. Diabetes Obes Metab. 2011;13(4):337–47.

    Article  CAS  PubMed  Google Scholar 

  27. Fleck P, Christopher R, Covington P. Efficacy and safety of alogliptin monotherapy over 12 weeks in patients with type 2 diabetes [abstract no. 479-P]. Diabetes. 2008;57(Suppl 1):143.

    Google Scholar 

  28. Pratley RE, Reusch JE-B, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009;25(10):2361–71.

    Article  CAS  PubMed  Google Scholar 

  29. Rosenstock J, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1C without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009;11(12):1145–52.

    Article  CAS  PubMed  Google Scholar 

  30. Pratley RE, Kipnes MS, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009;11(2):167–76.

    Article  CAS  PubMed  Google Scholar 

  31. Noda Y, Miyoshi T, Oe H, et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovasc Diabetol. 2013;12:8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Kato S, Kirigaya H, Gyotoku D, et al. DPP-4 inhibition by alogliptin improves the coronary flow reserve evaluated by phase contrast cine magnetic resonance imaging in type 2 diabetic patients with coronary artery disease [abstract no. 16542]. In: 86th Annual Scientific Sessions of the American Heart Association. 2013.

  33. Yamauchi Y, Tunekawa S, Seino Y, et al. The effect of DPP-4 inhibitor, alogliptin, on bone metabolism in patients with type 2 diabetes mellitus [abstract no. 1071-P]. In: 73rd Annual Scientific Sessions of the American Diabetes Association. 2013.

  34. Karim A, Harris S, Fleck P, et al. Assessment of drug interaction between alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, and warfarin at steady state [abstract no. 106]. J Clin Pharmacol. 2007;47(9):1207.

    Google Scholar 

  35. Karim A, Covington P, Christopher R, et al. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther. 2010;48(1):46–58.

    Article  CAS  PubMed  Google Scholar 

  36. European Medicines Agency. Vipidia (alogliptin): EU public assessment report. 2013. http://www.ema.europa.eu/. Accessed 3 Mar 2015.

  37. Karim A, Fleck P, Hetman L, et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment [abstract no. 538-P]. In: 68th Annual Scientific Sessions of the American Diabetes Association. 2008.

  38. Karim A, Fleck P, Dorsey D, et al. Single-dose pharmacokinetics of alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, in subjects with moderate hepatic impairment [abstract no. 107]. J Clin Pharmacol. 2007;47(9):1207.

    Google Scholar 

  39. Karim A, Fleck P, Harrell RE, et al. Effects of age, race, and gender on the pharmacokinetics and pharmacodynamics of alogliptin, a novel and highly selective dipeptidyl peptidase-4 inhibitor in healthy subjects [abstract no. PI-14]. Clin Pharmacol Ther. 2008;83(Suppl 1):S13.

    Google Scholar 

  40. Karim A, Fleck P, Harris S, et al. Effect of fluconazole, ketoconazole, and gemfibrozil on the pharmacokinetics of alogliptin benzoate (SYR-322) in healthy subjects [abstract no. 105]. J Clin Pharmacol. 2007;47(9):1207.

    Google Scholar 

  41. Karim A, Laurent A, Munsaka M, et al. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol. 2009;49(10):1210–9.

    Article  CAS  PubMed  Google Scholar 

  42. Karim A, Fleck P, Harris S, et al. Lack of pharmacokinetic interaction between multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin and digoxin in healthy subjects [abstract no. PI-13]. Clin Pharmacol Ther. 2008;83(Suppl 1):S12–3.

    Google Scholar 

  43. Karim A, Fleck P, Harris S, et al. Assessment of drug interaction between alogliptin, a highly selective dipeptidyl peptidase-4 inhibitor, and atorvastatin in healthy subjects [abstract no. PI-17]. Clin Pharmacol Ther. 2008;83(Suppl 1):S14.

    Google Scholar 

  44. Karim A, Chiselko P, Fleck P, et al. Lack of effect of cyclosporine on the single-dose pharmacokinetics of alogliptin, a novel dipeptidyl peptidase-4 inhibitor, in healthy subjects [abstract no. PI-15]. Clin Pharmacol Ther. 2008;83(Suppl 1):S13.

    Google Scholar 

  45. Karim A, Copa A, Fleck P, et al. Effects of alogliptin on the pharmacokinetics and pharmacodynamics of norethindrone and ethinyl estradiol (Ortho-Novum® 1/35) in healthy adult female subjects [abstract no. PI-16]. Clin Pharmacol Ther. 2008;83(Suppl 1):S14.

    Google Scholar 

  46. DeFronzo RA, Fleck PR, Wilson CA, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31(12):2315–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Ji Q, Han P, Li C, et al. Efficacy and safety of alogliptin in subjects with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 study in mainland China, Taiwan and Hong Kong [abstract no. 915]. In: 49th Annual Meeting of the European Association for the Study of Diabetes. 2013.

  48. Rosenstock J, Inzucchi SE, Seufert J, et al. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care. 2010;33(11):2406–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Bosi E, Ellis GC, Wilson CA, et al. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011;13(12):1088–96.

    Article  CAS  PubMed  Google Scholar 

  50. DeFronzo RA, Burant CF, Fleck P, et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012;97(5):1615–22.

    Article  CAS  PubMed  Google Scholar 

  51. Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab. 2013;15(10):906–14.

    Article  CAS  PubMed  Google Scholar 

  52. Del Prato S, Camisasca R, Wilson C, et al. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014;16(12):1239–46.

    Article  PubMed  Google Scholar 

  53. Kaku K, Mori M, Kanoo T, et al. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. Expert Opin Pharmacother. 2014;15(15):2121–30.

    Article  CAS  PubMed  Google Scholar 

  54. Nakamura Y, Inagaki M, Shimizu T, et al. Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study. Nephron Clin Pract. 2013;123(1–2):46–51.

    Article  CAS  PubMed  Google Scholar 

  55. Fujii Y, Abe M, Higuchi T, et al. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opin Pharmacother. 2013;14(3):259–67.

    Article  CAS  PubMed  Google Scholar 

  56. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.

    Article  CAS  PubMed  Google Scholar 

  57. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015. doi:10.1016/S0140-6736(14)62225-X.

    PubMed  Google Scholar 

  58. Data on file, Takeda, 2014.

  59. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–79.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. Standards of medical care in diabetes: 2013. Diabetes Care. 2013;36 Suppl 1:S11–66.

  61. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19(2):327–36.

    Article  PubMed  Google Scholar 

  62. Charbonnel B, Schweizer A, Dejager S. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? Hosp Pract (Minneap). 2013;41(2):93–107.

    Article  Google Scholar 

  63. Berhan A, Berhan Y. Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. BMC Endocrine Disord. 2013;13:9.

    Article  CAS  Google Scholar 

  64. Bourdel-Marchasson I, Schweizer A, Dejager S. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract. 2011;39(1):7–21.

    Article  Google Scholar 

  65. Pratley RE. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2009;10(3):503–12.

    Article  CAS  PubMed  Google Scholar 

  66. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.

    Article  CAS  PubMed  Google Scholar 

  67. McMurray JJV, Ponikowski P, Bolli GB, et al. The Vildagliptin in Ventricular Dysfunction Diabetes trial (VIVIDD) [late-breaking abstract]. In: Heart Failure 2013. 2013.

  68. Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013;166(6):983–9.

    Article  CAS  PubMed  Google Scholar 

  69. Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diabetes Vasc Dis Res. 2013;10(4):289–301.

    Article  Google Scholar 

  70. Katakami N, Mita T, Yoshii H, et al. Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). J Atheroscler Thromb. 2013;20(12):893–902.

    Article  PubMed  Google Scholar 

  71. Singh S, Chang H-Y, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534–9.

    Article  CAS  PubMed  Google Scholar 

  72. Faillie J-L, Babai S, Crépin S, et al. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. Acta Diabetol. 2014;51(3):491–7.

    CAS  PubMed  Google Scholar 

  73. Scheen A. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opin Drug Saf. 2013;12(4):545–57.

    Article  CAS  PubMed  Google Scholar 

  74. Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62(7):2595–604.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Yang L, He Z, Tang X, et al. Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis. Eur J Gastroenterol Hepatol. 2013;25(2):225–31.

    Article  CAS  PubMed  Google Scholar 

  76. Brodovicz KG, Kou TD, Alexander CM, et al. Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk. Diabetes Obes Metab. 2012;14(12):1123–8.

    CAS  PubMed  Google Scholar 

  77. Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27(Suppl 3):57–64.

    Article  CAS  PubMed  Google Scholar 

  78. Gokhale M, Sturmer T, Gray C, et al. Dipeptidyl peptidase 4 inhibitors and comparative pancreatic cancer risk [abstract no. 111-LB]. In: 73rd Scientific Sessions of the American Diabetes Association. 2013.

  79. Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther. 2011;33(11):1609–29.

    Article  CAS  PubMed  Google Scholar 

  80. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16(1):48–56.

    Article  CAS  PubMed  Google Scholar 

  81. Faillie JL, Azoulay L, Patenaude V, et al. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ. 2014;348:g2780.

    Article  PubMed Central  PubMed  Google Scholar 

  82. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs: FDA and EMA assessment. N Engl J Med. 2014;370(9):794–7.

    Article  CAS  PubMed  Google Scholar 

  83. Monami M, Dicembrini I, Antenore A, et al. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011;34(11):2474–6.

    Article  PubMed Central  PubMed  Google Scholar 

  84. Marino AB, Cole SW. Alogliptin: safety, efficacy, and clinical implications. J Pharm Pract. 2015;28(1):99–106.

    Article  PubMed  Google Scholar 

  85. Bron M, Ferrufino CP, Samyshkin Y, et al. Evaluation of the pharmacy budget impact of alogliptin plus pioglitazone fixed dose combination in the treatment of type-2 diabetes mellitus [abstract no. PDB25]. Value Health. 2013;16(3):A160.

    Article  Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. Gillian Keating is a salaried employee of Adis/Springer. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand

    Gillian M. Keating

Authors
  1. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Additional information

The manuscript was reviewed by: I. Bourdel-Marchasson, Department of Gerontology-Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; K. Kaku, Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan; P. Marchetti, Department of Clinical and Experimental Medicine, University of Pisa, Cisanello AOUP University Hospital, Pisa, Italy; J. Neumiller, College of Pharmacy, Washington State University, Spokane, WA, USA; M. Rendell, School of Medicine, Creighton University, and Association of Diabetes Investigators, Creighton Diabetes Center, Omaha, NB, USA.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keating, G.M. Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 75, 777–796 (2015). https://doi.org/10.1007/s40265-015-0385-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0385-y

Keywords

Search

Navigation